ABUS · Arbutus Biopharma Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $179.13M | - | $529.0K | $10.74M | $1.76M | - | $1.34M | $1.73M | $1.53M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $4.12M | - | $5.78M | $5.50M | $8.96M | - | $14.27M | $15.55M | $15.40M | - |
| SG&A | $5.89M | - | $3.04M | $3.33M | $5.83M | - | $4.54M | $7.55M | $5.31M | - |
| Total Operating Expenses | $10.22M | - | $9.19M | $9.25M | $27.46M | - | $22.78M | $23.31M | $20.89M | - |
| D&A | $11.0K | - | - | - | $330.0K | - | - | - | $355.0K | - |
| Operating Income | $168.91M | - | ($8.66M) | $1.49M | ($25.70M) | - | ($21.44M) | ($21.58M) | ($19.36M) | - |
| Interest Expense | $17.0K | - | $23.0K | $34.0K | $44.0K | - | $46.0K | $34.0K | $44.0K | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | $169.69M | - | ($7.74M) | $2.52M | ($24.53M) | - | ($19.72M) | ($19.80M) | ($17.88M) | - |
| EPS - Basic | $0.88 | - | ($0.04) | $0.01 | ($0.13) | - | ($0.10) | ($0.11) | ($0.10) | - |
| EPS - Diluted | $0.87 | - | ($0.04) | $0.01 | ($0.13) | - | ($0.10) | ($0.11) | ($0.10) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $23.71M | $18.01M | $22.41M | $37.41M | $37.08M | $36.33M | $31.85M | $62.79M | $43.10M | $26.29M |
| Accounts Receivable | $1.31M | $1.45M | $905.0K | $1.02M | $1.18M | $2.41M | $1.61M | $1.77M | $2.14M | $1.78M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.46M | $1.17M | $1.01M | $1.32M | $2.24M | $2.32M | $2.31M | $2.65M | $3.74M | $3.22M |
| Current Assets | $277.01M | $94.46M | $97.44M | $103.12M | $116.81M | $127.32M | $132.78M | $148.22M | $135.87M | $132.03M |
| Total Assets | $277.16M | $94.62M | $97.71M | $103.27M | $117.01M | $131.71M | $140.44M | $160.04M | $150.29M | $144.40M |
| Current Liabilities | $5.11M | $6.01M | $5.18M | $5.02M | $19.43M | $15.62M | $18.92M | $22.59M | $20.30M | $22.49M |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $16.99M | $18.04M | $20.31M | $20.29M | $37.85M | $34.34M | $33.55M | $37.59M | $35.65M | $38.38M |
| Stockholders' Equity | $260.18M | $76.58M | $77.40M | $82.98M | $79.16M | $97.37M | $106.89M | $122.45M | $114.64M | $106.02M |
| Retained Earnings | ($1.21B) | ($1.38B) | ($1.38B) | ($1.37B) | ($1.37B) | ($1.35B) | ($1.33B) | ($1.31B) | ($1.29B) | ($1.28B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.11M) | - | - | - | ($13.39M) | - | - | - | ($19.30M) | - |
| Investing Cash Flow | $2.20M | - | - | - | $11.35M | - | - | - | $11.69M | - |
| Financing Cash Flow | $11.62M | - | - | - | $2.78M | - | - | - | $24.43M | - |
| CapEx | - | - | - | - | $0 | - | - | - | $95.0K | - |
| Free Cash Flow | - | - | - | - | ($13.39M) | - | - | - | ($19.39M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 94.3% | - | -1636.9% | 13.9% | -1456.9% | - | -1601.2% | -1250.5% | -1263.9% | - |
| EBITDA margin | 94.3% | - | - | - | -1438.2% | - | - | - | -1240.7% | - |
| Net margin | 94.7% | - | -1463.5% | 23.5% | -1390.4% | - | -1472.5% | -1146.9% | -1166.8% | - |
| Free cash flow margin | - | - | - | - | -759.1% | - | - | - | -1265.7% | - |
| FCF / Net income | - | - | - | - | 0.55 | - | - | - | 1.08 | - |
| R&D / Revenue | 2.3% | - | 1092.2% | 51.2% | 507.9% | - | 1065.9% | 901.0% | 1005.4% | - |
| SG&A / Revenue | 3.3% | - | 575.4% | 31.0% | 330.6% | - | 338.8% | 437.3% | 346.7% | - |
| Effective tax rate | 0.0% | - | - | - | - | - | - | - | - | - |
| Return on assets | 61.2% | - | -7.9% | 2.4% | -21.0% | - | -14.0% | -12.4% | -11.9% | - |
| Return on equity | 65.2% | - | -10.0% | 3.0% | -31.0% | - | -18.4% | -16.2% | -15.6% | - |
| Return on invested capital | 64.9% | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 54.26 | 15.73 | 18.80 | 20.53 | 6.01 | 8.15 | 7.02 | 6.56 | 6.69 | 5.87 |
| Quick ratio | 54.26 | 15.73 | 18.80 | 20.53 | 6.01 | 8.15 | 7.02 | 6.56 | 6.69 | 5.87 |
| Cash ratio | 4.64 | 3.00 | 4.32 | 7.45 | 1.91 | 2.33 | 1.68 | 2.78 | 2.12 | 1.17 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | 0.00 | - | - | - | - | - | - | - | - | - |
| Interest coverage | 9935.8x | - | -376.5x | 43.8x | -584.1x | - | -466.1x | -634.8x | -440.1x | - |
| Equity multiplier | 1.07 | 1.24 | 1.26 | 1.24 | 1.48 | 1.35 | 1.31 | 1.31 | 1.31 | 1.36 |
| Liabilities / Assets | 0.06 | 0.19 | 0.21 | 0.20 | 0.32 | 0.26 | 0.24 | 0.23 | 0.24 | 0.27 |
| Efficiency | ||||||||||
| Asset turnover | 0.65 | - | 0.01 | 0.10 | 0.02 | - | 0.01 | 0.01 | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 3d | - | 624d | 35d | 245d | - | 438d | 374d | 510d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 5.2x | - | - | 309.0x | - | - | - | - | - | - |
| P / B | 3.4x | - | 11.2x | 7.2x | 8.4x | - | 6.8x | 4.7x | 4.0x | - |
| P / S | 4.9x | - | 1645.9x | 55.4x | 377.3x | - | 543.4x | 336.6x | 295.8x | - |
| EV / EBITDA | 5.1x | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 10054.5% | - | -60.5% | 522.2% | 15.1% | - | -71.3% | -62.9% | -77.1% | - |
| Revenue CAGR (3y) | 199.2% | - | -55.4% | -9.0% | -48.0% | - | -26.3% | -9.5% | -10.2% | - |
| Revenue CAGR (5y) | 143.0% | - | -19.1% | 48.0% | 3.4% | - | -15.2% | 21.5% | 17.7% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 59.6% | - | -32.7% | - | 0.5% | -17.4% | -11.2% | - |
| Net income growth (YoY) | - | - | 60.7% | - | -37.2% | - | 1.9% | -15.8% | -9.4% | - |
| EPS growth (YoY) | - | - | 60.0% | - | -30.0% | - | 16.7% | -10.0% | 0.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 30.9% | - | - | - | 29.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 228.7% | -21.4% | -27.6% | -32.2% | -30.9% | -8.2% | -10.4% | -9.1% | -20.3% | -22.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$14.08M totalReportable Segment$14.08M · 100.0%
Product / service
$15.75M totalCollaboration And Contracts$12.60M · 80.0%
License$1.67M · 10.6%
Non Cash Royalty$1.48M · 9.4%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Arbutus Biopharma Corp against the 5 most active filers in the same SIC group.